Document Detail


Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial.
MedLine Citation:
PMID:  19907167     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Thrombolysis with recombinant tissue plasminogen activator (rt-PA) is currently the only approved acute therapy for ischemic stroke. After rt-PA-induced recanalization, reocclusion is observed in 20-34%, probably caused by platelet activation. In acute myocardial infarction, the combination of thrombolytic and antiplatelet therapy leads to a better outcome compared to thrombolytic treatment alone. In patients with acute ischemic stroke, several studies showed that those on antiplatelet treatment prior to rt-PA had an equal or even better outcome compared to patients without prior use of antiplatelet therapy, despite an increased risk of bleeding. METHODS: We present the protocol of a multicenter randomized clinical trial (n = 800) investigating the effects of immediate addition of aspirin to rt-PA on poor outcome (modified Rankin score >2) in ischemic stroke patients. CONCLUSION: This study will answer the question whether the combination of rt-PA and antiplatelet therapy improves the functional outcome in ischemic stroke patients.
Authors:
S M Zinkstok; M Vermeulen; J Stam; R J de Haan; Y B Roos
Related Documents :
9161657 - Cost-effectiveness of thrombolytic therapy for acute myocardial infarction.
2584547 - Long-term benefit of early thrombolytic therapy in patients with acute myocardial infar...
8279357 - Use of composite endpoints in thrombolysis trials of acute myocardial infarction.
12528307 - Third generation thrombolytics for the treatment of ischemic stroke.
12928207 - Ventricular reshaping with devices.
1623787 - Pacemaker-induced friction rub and apical thrill.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-11-10
Journal Detail:
Title:  Cerebrovascular diseases (Basel, Switzerland)     Volume:  29     ISSN:  1421-9786     ISO Abbreviation:  Cerebrovasc. Dis.     Publication Date:  2010  
Date Detail:
Created Date:  2009-12-09     Completed Date:  2010-02-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100851     Medline TA:  Cerebrovasc Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  79-81     Citation Subset:  IM    
Affiliation:
Department of Neurology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. s.m.zinkstok@amc.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aspirin / adverse effects,  therapeutic use*
Brain Ischemia / complications,  drug therapy*
Drug Therapy, Combination
Fibrinolytic Agents / administration & dosage*,  adverse effects
Humans
Intracranial Hemorrhages / chemically induced
Netherlands
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use*
Prospective Studies
Recombinant Proteins / administration & dosage
Research Design*
Stroke / drug therapy*,  etiology
Thrombolytic Therapy* / adverse effects
Time Factors
Tissue Plasminogen Activator / administration & dosage*,  adverse effects
Treatment Outcome
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 0/Recombinant Proteins; 50-78-2/Aspirin; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-Term Oral Anticoagulation Therapy and the Risk of Hip Fracture in Patients with Previous Hemisp...
Next Document:  D-Dimers Predict Stroke Subtype when Assessed Early.